In 2007, an ambitions team of medical experts founded Medisure medical in the UAE with a goal of improving lives and delivering crucial heart treatment to sufferers across the region. After considerable success, Medisure was transformed again in 2016, when a group of industry leaders and powerful investors who brought more than 15 years of experience marketing medical equipment joined the company. With that extra backing and expertise, Medisure was in a position to expand its goals and expand its portfolio, offering more specialized treatment to more people, changing even more lives throughout the UAE.
Today, as part of Cardiovascular core therapies, we have brought new, innovate and effective solutions in a number of diverse fields, including Neuro Surgery, Spine and Orthopaedic Surgery, Neurology and General Surgery, delivering life-changing approaches to long term suffering. Our vision and drive is focused on improving the condition of chronic disease patients through cutting-edge medical technology, innovative therapies and constant improvement. Our team works tirelessly in partnership with partners throughout the industry, refining proven treatments and new approaches to provide effective treatment that transforms lives and delivers a brighter future for patients across the country.
Our extensive record in the UAE has established us as a leader in our field, bringing a host of new approaches to the country and our patients, including:
- Robotic Surgery
- Surgical Head Mounted Microscope
- Deep Brain Stimulation
- Bioresorbable Coronary stent
- Cardiac Ventricle Assist Device
- Transcatheter Aortic Valve Replacement
- Transcatheter Mitral Valve Repair
- ECG Mobile Cardiac Telemetry
- Medical 3D Printing
Our journey does not end here though, our commitment to identify, evaluate, refine and introduce new treatments to the UAE for the first time in order to ease suffering and change lives remains as strong as ever. We will continue to work with our partners and healthcare providers to deliver effective treatment.
CEO Message
"To deliver innovative therapeutic and diagnostic solutions that protect human and cure patients"
As medical technology advances rapidly, established ideas of treatment are constantly being challenged, and we are right at the forefront of that, leading the adoption of new thinking and innovation. Through effective relationships with industry partners, healthcare providers and physicians across the UAE, we identify, refine and deliver new treatments, new technological approaches, and new ideas to ease the suffering of patients with chronic disease. Our goal is to transform lives through medical innovation, today and into the future.
- Building a real partnership with healthcare providers and physicians, to introduce new solutions for patients.
- Continuous development to our team that will satisfy our clients and patients.
- Helping healthcare providers to adopt new solutions by conducting workshop and required trainings.
- To be ethical, responsible and knowledgeable.
- To put our customers & patients first.
- To work with integrity and honesty.
In the year 2000 we entered the interventional cardiology market and immediately became the first cardiology company to develop and patent their own proprietary limus agent, Biolimus A9™ (BA9™), a highly lipophilic1 anti-restenotic drug designed for cardiovascular stent technologies. We were also the first stent company to develop and launch a biodegradable polymer stent with only the abluminal side coated with polymer and drug to reduce systemic exposure2.
During the last 60-years, Cordis established a legacy of pioneering breakthrough technologies, including the first guiding catheters and coronary drug eluting stents. It has built a strong global footprint that spans 70 countries.
Cordis committed to saving millions of lives through innovation, clinical acumen, training, and service. Its mission is to delight customers by developing differentiated solutions at a pace that improves patient vitality and helps lower the cost of care.
Cordis will continue innovating and will continue to focus on vascular closure, radial and pedal access, and intervention as they look to the future to address the toughest cardiovascular challenges.
Asahi Intecc develops, produces and sells various medical devices required for catheter treatment. Treatment areas where these devices are used is not limited to cardiovascular system areas but also extends to areas of the peripheral vascular system, abdominal vascular system, cerebrovascular system and other areas. With ASAHI outstanding development capabilities and production technologies in the medical device field, they hold a high share not just in the Japanese market but also globally.
During the last 60-years, Cordis established a legacy of pioneering breakthrough technologies, including the first guiding catheters and coronary drug eluting stents. It has built a strong global footprint that spans 70 countries.
Cordis committed to saving millions of lives through innovation, clinical acumen, training, and service. Its mission is to delight customers by developing differentiated solutions at a pace that improves patient vitality and helps lower the cost of care.
Cordis will continue innovating and will continue to focus on vascular closure, radial and pedal access, and intervention as they look to the future to address the toughest cardiovascular challenges.
CNSystems’ core technologies are made for painless and reliable cardiovascular diagnosis, monitoring and therapy control in order to improve patient care and medical outcome. The company has achieved technological leadership in developing a noninvasive, easy-to-use and accurate diagnosis and patient monitoring systems for better and easier insights into the cardiovascular system and its control mechanism located in the brain.
In the year 2000 we entered the interventional cardiology market and immediately became the first cardiology company to develop and patent their own proprietary limus agent, Biolimus A9™ (BA9™), a highly lipophilic1 anti-restenotic drug designed for cardiovascular stent technologies. We were also the first stent company to develop and launch a biodegradable polymer stent with only the abluminal side coated with polymer and drug to reduce systemic exposure2.
Istem Medical is an establishment that takes place in the sales and marketing area of the medical sector since 1995. Today Istem Medikal has become the leader of the sector which has also started to export aiming to get first place in the international arena.
Istem Medicals vision is to accelerate the development of the health sector doing the best that possible.ISTEM MEDICAL that has EN ISO 9001:2015 and EN ISO: 13485:2016 quality certificates aims to be the pioneer in the sector.
LSI SOLUTIONS was founded in 1986 by Jude S. Sauer, M.D., with a mission to lead the world in medical product innovation and passion to focus on patient outcomes. What once started with a focus on laser tissue welding has evolved into a world-renowned company dedicated to advancing minimally invasive therapeutics through research, development, manufacturing, and marketing of proprietary products.
Grena Ltd is an innovative manufacturer of disposable medical devices. With the central focus on patients’ safety and users’ comfort we offer high-quality products. Experience gathered throughout over 25 years of being active in the healthcare field has allowed us to grow into an internationally recognizable healthcare brand.
In cooperation with surgeons, we deliver real products for the real needs of specialists. Constantly on the move, you can meet us all around the world during the biggest exhibition fairs, international events, and dedicated workshops.
Founded in Sweden in 2012, IRRAS is a commercial medical device company, focused on designing, developing, and commercializing innovative solutions that transform fluid management after surgical procedures where drainage is required
Copyright © 2024.
Medisure Medical. All Rights Reserved